Should I snap up GSK shares at £14?

The GSK share price has slumped. Should investors pile in or steer clear? Roland Head investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Shares in FTSE 100 pharmaceutical firm GSK (LSE: GSK) are now worth about 15% less than they were at the start of August.

GSK’s share price has tumbled as investors have priced in the potential costs of legal claims that heartburn medicine Zantac causes cancer.

However, this UK healthcare stock is now trading on just 11 times forecast earnings, with a dividend yield over 4%.

If management are correct to dismiss the Zantac cancer claims as “meritless”, I think GSK shares could be decent value at this level.

Could GSK shares go to zero?

GSK is facing around 3,000 individual personal injury claims in the US, plus a larger group action in Florida.

The company says that “the overwhelming weight of the scientific evidence” suggests that there is no increased cancer risk associated with Zantac. However, even if this is accepted in court, the legal process could be long and expensive.

It’s not possible to find a direct comparison to this situation. But I think it’s interesting to note that German chemicals group Bayer has so far allocated $16bn to settle long-running claims that Roundup weedkiller causes cancer.

In my view, it’s sensible to assume that GSK will face substantial costs relating to these claims. However, I don’t think there’s any doubt that the company will survive.

After all, GSK currently generates around £5bn a year of surplus cash.

I think the worst that’s likely to happen is that management might have to scale back growth investments and perhaps cut the dividend, in order to fund settlements.

What else do I need to know?

I’m not going to spend time trying to guess at the outcome of the Zantac trials. Instead, I’ve been taking a look at GSK’s recent trading. Is this healthcare business on track to deliver rising profits this year?

GSK has now split from its consumer healthcare division, Haleon (which might also face Zantac costs). This split means that GSK is now a pure-play pharma business with three divisions: vaccines, specialty medicines (eg, cancer treatments), and general medicines (eg, asthma inhalers).

Sales from these three divisions rose by 28% to £14,199m during the first half of this year. Adjusted operating profit rose by 33% to £3,951m during the same period.

CEO Emma Walmsley’s latest guidance for 2022 suggests that full-year sales should rise by around 6%-8%. Adjusted operating profit is expected to be 13%-15% higher.

When profits rise more quickly than sales like this, it tells me that profit margins are improving. That’s good news, too.

GSK share price: buy, sell, or hold?

I’ve learned from experience to be cautious about investing in companies with uncertain legal liabilities. In the US, especially, these can often end up higher than anyone expected.

However, GSK is a large, profitable business, and its debt levels should be lower following the Haleon split. I think the risks from the Zantac claims should be manageable.

For long-term investors, I think GSK could be a solid buy at current levels.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK plc and Haleon plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

High flying easyJet women bring daughters to work to inspire next generation of women in STEM
Investing Articles

In 12 months, a £10,000 investment in easyJet shares could become…

easyJet shares have plunged in value following a profit warning on Thursday (17 July). Can the FTSE 100 travel share…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

This S&P 500 blue chip looks far too cheap to me at $183!

Our writer picks out one high-quality S&P 500 stock that is currently the cheapest among the 'Magnificent 7' group of…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Down 23% today! This one’s stinking out my Stocks and Shares ISA

Our writer's wondering what to do with a problem named Ashtead Technology (LON:AT.) in his Stocks and Shares ISA portfolio.

Read more »

Two male friends are out in Tynemouth, North East UK. They are walking on a sidewalk and pushing their baby sons in strollers. They are wearing warm clothing.
Investing Articles

Down over 20%, should I dump this FTSE 100 dividend stock?

Our writer has been loving the passive income this dividend stock has been throwing off. But does the big share…

Read more »

Businesswoman calculating finances in an office
Investing Articles

I’ve just bought this FTSE share…

Our writer explains the thought process that led to him buying this FTSE share. One that’s likely to do well…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Just over £5 now, easyJet’s share price looks cheap to me anywhere under £13.84

easyJet’s share price has dropped recently, which could mean the business is worth less than before. Conversely, it could mean…

Read more »

Trader on video call from his home office
Investing Articles

36% under ‘fair value’ and forecast annual earnings growth of 6%, should investors consider this FTSE 250 stock?  

This FTSE 250 firm is a leader in a growing sector and has secured several new sites to drive its…

Read more »

Portrait of a boy with the map of the world painted on his face.
Investing Articles

3 UK shares that have recently become takeover targets

Mark Hartley examines why these three UK shares have become takeover targets and could be bought out by rivals in…

Read more »